MyFinsight
Home
Blog
About
Contact
Back
Income Statement
Metagenomi Therapeutics, Inc. (MGX)
Metagenomi Therapeutics, Inc. (MGX)
source: myfinsight.com
Comprehensive loss
-$23,363K
(7.02%↑ Y/Y)
Net loss
-$23,059K
(7.91%↑ Y/Y)
Unrealized loss on
available-for-sale marketable...
-$304K
(-245.45%↓ Y/Y)
Interest income
$1,539K
(-46.69%↓ Y/Y)
Net loss before
provision for income taxes
-$23,049K
(7.59%↑ Y/Y)
Provision for income taxes
$10K
(-89.80%↓ Y/Y)
Total other income,
net
$1,538K
(-46.58%↓ Y/Y)
Other expense, net
-$1K
(87.50%↑ Y/Y)
Loss from operations
-$24,587K
(11.62%↑ Y/Y)
Collaboration revenue
$1,248K
(-69.76%↓ Y/Y)
Total operating
expenses
$25,835K
(-19.13%↓ Y/Y)
Research and development
$19,300K
(-23.24%↓ Y/Y)
General and
administrative
$6,535K
(-3.97%↓ Y/Y)
Back